Novel nitrofuran-containing heterocyclic compounds and uses thereof

A compound of the formula:

• 11
• wherein,
• Each X is independently selected from CR2, NR2, O, S, or N;
• Each Y is independently selected from CR2, NR2, O, S, or N;
• Each Z is independently selected from CR2, NR2, O, S, or N;
• Each R1 is independently selected from SH, SO3H, SO2NH2, SO2NR3R3, S(CH2)nOH, OR3, S(CH2)nOC(O)R3, or SR3;
• Each n is independently 1, 2 or 3;
• Each R2 is independently selected from H, C1-C10 alkyl;
• C2-C10 alkenyl;
• C2-C10 alkynyl;
• C3-C10 cycloalkyl;
• aryl optionally substituted with 1-4 independent R5;
• heteroaryl optionally substituted with 1-4 independent R5;
• heterocyclyl optionally substituted with 1-4 independent R5;
• and C1-C10 alkyl substituted with R4 or R8;
• Each R3 is independently selected from H, C1-C10 alkyl;
• C2-C10 alkenyl;
• C2-C10 alkynyl;
• C3-C10 cycloalkyl;
• aryl optionally substituted with 1-4 independent R5;
• heteroaryl optionally substituted with 1-4 independent R5;
• heterocyclyl optionally substituted with 1-4 independent R5;
• and C1-C10 alkyl substituted with R4 or R8;
• Each R4 is independently selected from halogen, CF3, SR6, OR6, OC(O)R, NR6R6, NR6R7, COOR6, NO2, CN, C(O)R6, or C(O)NR6R6;
• Each R5 is independently selected from C1-C10 alkyl;
• C2-C10 alkenyl;
• C2-C10 alkynyl;
• C3-C10 cycloalkyl;
• C4-C10 cycloalkenyl;
• halo;
• haloalkyl;
• SR6;
• OR6;
• NR6R6;
• NR6R7;
• COOR6;
• NO2;
• CN;
• C(O)R6;
• C(O)NR6R6;
• OC(O)R6;
• S(O)2R6;
• S(O)2NR6R6;
• NR6C(O)N R6R6;
• NR6C(O)R6;
• NR6(COOR6);
• NR6C(O)R8;
• NR6S(O)2NR6R6;
• NR6S(O)2R6;
• NR6S(O)2R8;
• and C1-C10 alkyl substituted with R4 or R8;
• Each R6 is independently selected from H, C1-C10 alkyl;
• C2-C10 alkenyl;
• C2-C10 alkynyl;
• C3-C10 cycloalkyl;
• R8;
• and C1-C10 alkyl substituted with R8 or R10;
• Each R7 is independently selected from C(O)R9, COOR9;
• Each R8 is independently selected from aryl, heteroaryl or heterocyclyl, each optionally substituted with 1-4 independent R10;
• Each R9 is independently C1-C10 alkyl, aryl, heteroaryl, or heterocyclyl, each optionally substituted with 1-4 independent R10;
• Each R10 is independently halogen, CF3, SR11, OR11, OC(O)R11, NR11R11, NR11R7, COOR11, NO2, CN, C(O)R11, or C(O)NR11R11;
• Each R11 is independently selected from H, C1-C10 alkyl or aryl, each optionally substituted with halogen, SR12, OR12, OC(O)R12, or NR12R12;
• Each R12 is independently selected from H, C1-C10 alkyl, heteroaryl, heterocyclyl, or aryl;
• Each aryl is independently a 6-carbon monocyclic or 10-carbon bicyclic aromatic ring system wherein 0, 1, 2 or 3 atoms of each ring may be substituted by a substituent;
• Each heteroaryl is independently an aromatic 5-8 membered monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic ring system comprising 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from O, N, or S, wherein 0, 1, 2 or 3 atoms of each ring may be substituted by a substituent;
• and
• Each heterocyclyl is independently a nonaromatic 5-8 membered monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic ring system comprising 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from O, N, or S, wherein 0, 1, 2 or 3 atoms of each ring may be substituted by a substituent;
• or pharmaceutically acceptable salt thereof.